The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 07, 2021

Filed:

May. 12, 2020
Applicant:

H. Lundbeck A/s, Valby, DK;

Inventors:

Klaus Gjervig Jensen, Valby, DK;

Lisbet Kværnø, Valby, DK;

Morten Jørgensen, Valby, DK;

Martin Juhl, Valby, DK;

Assignee:

H. Lundbeck A/S, Valby, DK;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/706 (2006.01); A61P 25/00 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); A61K 31/473 (2006.01);
U.S. Cl.
CPC ...
A61K 31/706 (2013.01); A61K 31/473 (2013.01); A61P 25/00 (2018.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01);
Abstract

The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease. Accordingly, the present invention relates to compounds of formula (Id) whereinR1 is H and R2 is selected from one of the substituents (i) and (ii) below; orR1 is selected from one of the substituents (i) and (ii) below and R2 is H; orR1 and R2 are both represented by substituent (i) below; orR1 and R2 are both represented by substituent (ii) below; orR1 is substituent (i) and R2 is substituent (ii); orR1 is substituent (ii) and R2 is substituent (i); wherein * indicates the attachment point; andwherein the carbon atom at the attachment point on substituent (i) is in the S-configuration; or a pharmaceutically acceptable salt thereof.


Find Patent Forward Citations

Loading…